4577 — Daito Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00
- ¥39bn
- ¥43bn
- ¥45bn
- 54
- 74
- 82
- 85
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 4,619 | 5,595 | 5,874 | 6,720 | 5,076 |
Depreciation | |||||
Non-Cash Items | -60 | -225 | 105 | -174 | 30 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -523 | -4,015 | -3,951 | -5,488 | -4,820 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 6,888 | 4,306 | 5,183 | 4,371 | 4,156 |
Capital Expenditures | -3,663 | -2,773 | -6,350 | -4,733 | -5,556 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -205 | 91.8 | 25.3 | 333 | -10 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -3,867 | -2,681 | -6,324 | -4,400 | -5,566 |
Financing Cash Flow Items | -0.001 | 7.83 | -0.002 | 80 | -2 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2,898 | -350 | 1,425 | 989 | 616 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 108 | 1,265 | 289 | 1,008 | -774 |